The maintenance of a Buy rating suggests continued confidence in Cue Biopharma's potential, but the halving of the price target from $8 to $4 indicates a significant reduction in expected upside, likely due to revised financial forecasts or market conditions. This could lead to short-term negative sentiment among investors.